Market Overview

Early Keytruda Results Win Merck An Upgrade

Share:
Early Keytruda Results Win Merck An Upgrade

Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing.

The Analyst

SunTrust Robinson Humphrey's John Boris upgraded Merck's stock rating from Hold to Buy with a price target boosted from $54 to $72.

The Thesis

Merck was expected to report positive data, but the readout may have surprised investors, as it came "much earlier" than expected, Boris said in the upgrade note. (See the analyst's track record here.) 

The "significantly longer [overall survival and progression-free survival]" readout should give the company the ability to sustain its first-mover advantage in the space, the analyst said. 

The objective response rate in the Keytruda study was almost double that of chemotherapy alone, Boris said. 

The median progression-free survival rate showed "a significant improvement," and about 75 percent of patients in the chemo segment who discontinued treatment then crossed over to the Keytruda and chemo combination, he said. 

Price Action

Shares of Merck were trading higher by nearly 7 percent at the time of publication. 

Related Links:

The Bull Thesis For Merck Is Evaporating

Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application

Latest Ratings for MRK

DateFirmActionFromTo
Aug 2019Initiates Coverage OnOutperform
Jul 2019Initiates Coverage OnBuy
Jun 2019MaintainsOverweight

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: cancer Cancer DrugsAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Susquehanna Upgrades Lam Research On Favorable Industry Outlook

This Day In Market History: Operation Desert Storm